Krystal Biotech (KRYS) Change in Receivables (2023 - 2026)

Krystal Biotech has disclosed Change in Receivables across 4 years of filings, most recently posting -$58000.0 for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$58000.0, up 96.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.6 million (down 58.53% YoY), and the FY2025 annual result was $22.1 million, down 64.72% from the prior year.
• Change in Receivables came in at -$58000.0 for Q1 2026 at Krystal Biotech, up from -$2.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $56.8 million in Q2 2024 to a low of -$5.9 million in Q3 2024.
• The 4-year median for Change in Receivables is $7.4 million (2024), against an average of $11.5 million.
• Across the five-year window, Change in Receivables tumbled 163.75% in 2024 and surged 401.78% in 2025, its largest moves.
• Krystal Biotech's Change in Receivables stood at $32.7 million in 2023, then sank by 77.24% to $7.4 million in 2024, then plunged by 133.45% to -$2.5 million in 2025, then surged by 97.67% to -$58000.0 in 2026.
• The last three Change in Receivables figures came in at -$58000.0 (Q1 2026), -$2.5 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.